Surface plasmon resonance imaging (SPRi) binding assays were first performed using the protein and glycosaminoglycan (GAG) arrays we developed [33,45,46] comprised of 44 different biomolecules to identify new extracellular and membrane partners of LOXL2, which plays a prominent role in cancer, and of its N-terminal scavenger receptor cysteine-rich domains (SRCR). This evidence concerns the gene LOXL2 and cancer.